Betamethasone Dipropionate Emollient Spray vs Halobetasol Propionate Foam
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: Glucocorticoid receptor · full Psoriasis pipeline
Betamethasone Dipropionate Emollient Spray · Sernivo
Marketed by Primus Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Halobetasol Propionate Foam · Lexette
Rights held by Mayne Pharma; US product discontinued
NCT02742441 · Phase 3 · completed
The trial randomized 409 participants to active foam or vehicle foam and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical endpoint was met, with treatment success in 30.7% versus 7.4% of participants at Day 15 (p<0.001).
Reported efficacy
Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): 122-0551 Foam 30.7% vs Vehicle Foam 7.4% (met)
Result source: NCT02742441
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Betamethasone Dipropionate Emollient Spray | Halobetasol Propionate Foam |
|---|---|---|
| PASI 75 | —Not reported | —Not posted · NCT02367911 |
| PASI 90 | —Not reported | —Not posted · NCT02367911 |
| PASI 100 | —Not reported | —Not posted · NCT02367911 |
| sPGA 0/1 | —Not reported | —Not posted · NCT02367911 |
| DLQI, change | —Not reported | —Not posted · NCT02367911 |
PASI 75
- Betamethasone Dipropionate Emollient Spray
- —Not reported
- Halobetasol Propionate Foam
- —Not posted · NCT02367911
PASI 90
- Betamethasone Dipropionate Emollient Spray
- —Not reported
- Halobetasol Propionate Foam
- —Not posted · NCT02367911
PASI 100
- Betamethasone Dipropionate Emollient Spray
- —Not reported
- Halobetasol Propionate Foam
- —Not posted · NCT02367911
sPGA 0/1
- Betamethasone Dipropionate Emollient Spray
- —Not reported
- Halobetasol Propionate Foam
- —Not posted · NCT02367911
DLQI, change
- Betamethasone Dipropionate Emollient Spray
- —Not reported
- Halobetasol Propionate Foam
- —Not posted · NCT02367911
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Betamethasone Dipropionate Emollient Spray: registry results are on file for Psoriasis, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Betamethasone Dipropionate Emollient Spray: 0 of 4 rows · Halobetasol Propionate Foam: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Halobetasol Propionate Foam |
|---|---|
| Dropout rate | 2.9%a NCT02742441 · Phase 3 show 4 more results1.3% NCT02368210 · Phase 3 7% NCT02367911 · Phase 3 0% NCT01698333 · Phase 2 · registry result, not featured evidence 0% NCT01700985 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0%a NCT02742441 · Phase 3 show 4 more results0% NCT02368210 · Phase 3 — NCT02367911 · Phase 3 — NCT01698333 · Phase 2 · registry result, not featured evidence — NCT01700985 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%a NCT02742441 · Phase 3 show 4 more results0% NCT02368210 · Phase 3 0% NCT02367911 · Phase 3 0% NCT01698333 · Phase 2 · registry result, not featured evidence 0% NCT01700985 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a headache 1.5% (placebo 1.5%) application site pain 1% (placebo 0.5%) back pain 0.5% (placebo 0%) NCT02742441 · Phase 3 show 4 more resultsabdominal pain 1.3% (placebo 0%) application site pain 1.3% (placebo 0%) hordeolum 1.3% (placebo 0%) NCT02368210 · Phase 3 sinusitis 1.4% (placebo 0%) trichorrhexis 1.4% (placebo 0%) application site dryness 0% (placebo 1.4%) NCT02367911 · Phase 3 acth stimulation test abnormal 24% nasal congestion 4% pharyngitis 4% NCT01698333 · Phase 2 · registry result, not featured evidence influenza like illness 4.3% (placebo 0%) pharyngitis 0% (placebo 4.8%) upper respiratory tract infection 0% (placebo 9.5%) NCT01700985 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Halobetasol Propionate Foam
show 2 more results
show 4 more results
show 1 more result
show 2 more results
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Betamethasone Dipropionate Emollient Spray's landscape · Halobetasol Propionate Foam's landscape